Analysis of Red Blood Cell Integrity and Efficiency of Recovery Using a Novel Surgical Sponge-Blood Recovery Device (ProCell)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-89
SponsorUniversity Hospitals Cleveland Medical Center

About this trial

The purpose of this research study is to compare two methods of recovering blood from surgical sponges used during heart and lung surgeries. The two methods are: 1) manually wringing sponges by hand, and 2) automated wringing sponges by an FDA approved suction device. Both methods are already in use in heart and lung surgeries at University Hospitals at the discretion of the surgeon.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Undergoing heart or lung transplant, redo sternotomy, aortic surgery, and/or multi-valve repairs/replacements; and

At University Hospitals Cleveland Medical Center.

Disqualifiers

Patients with known bleeding disorders, including disseminated intravascular coagulation (DIC), prothrombin deficiency, factor V deficiency, factor VII deficiency, factor X deficiency, factor XI deficiency (hemophilia C), Glanzmann disease, hemophilia A, hemophilia B, idiopathic thrombocytopenic purpura (ITP), and Von Willebrand disease (types I, II, and III);

Patients undergoing emergent or emergent salvage surgery; and

Patients actively participating in another clinical trial which could affect outcomes.

Trial design

Design model

Crossover

Treatments tested in this trial

  • Hand Wrung

    Procedure/Surgery

    Hand wrung refers to manually wringing surgical sponges by hand.

  • ProCell Wrung

    Device

    ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).

Treatment groups

20 Participants
are divided into 2 treatment groups
Group A: Hand WrungActive comparator 1 intervention
Group B: ProCell WrungExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Level of Plasma Free Hemoglobin

Level of plasma free hemoglobin will be measured at baseline.

Time frame
Baseline
2

Level of Plasma Free Hemoglobin

Level of plasma free hemoglobin will be measured post-processing.

Time frame
Post-Processing (Up to 120 Minutes)
3

Change in Volume of Blood

Volume of blood will be measured at baseline and post-processing.

Time frame
Baseline, Post-Processing (Up to 120 Minutes)

Secondary outcomes

1

Number of Fragmented Red Blood Cells

Number of fragmented red blood cells will be measured at baseline.

Time frame
Baseline
2

Number of Fragmented Red Blood Cells

Number of fragmented red blood cells will be measured post-processing.

Time frame
Post-Processing (Up to 120 Minutes)
3

Level of Lactate Dehydrogenase

Level of lactate dehydrogenase will be measured at baseline.

Time frame
Baseline
4

Level of Lactate Dehydrogenase

Level of lactate dehydrogenase will be measured post-processing.

Time frame
Post-Processing (Up to 120 Minutes)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.